Data analysis of patients who received anti-SARS-CoV-2 vaccination with Pfizer vaccine in Italy

Many scenarios developed following the COVID-19 epidemic caused by SARSCoV-2 assume that the infection results in an immune response that confers immunity or reduces the severity of a possible reinfection. The presence or absence of protective immunity due to infection or vaccination will affect future transmission and disease severity. COVID-19 infection leads to the production of IgG and IgM class antibodies after a few days or weeks. However, it remains to be understood why the infection is sometimes not followed by antibody production in some subjects. IgG antibodies develop a secondary immune response, which occurs on subsequent exposures to the same antigen. In fact, these antibodies represent the "memory" of the immune system, to be able to intervene in the event of a subsequent infection. Taking as an example what happened in the course of the infections of other coronaviruses, some hypotheses can be made. For example in Severe Acute Respiratory Syndrome (SARS) (caused by the SARS-Cov-1 virus) the antibody response lasted 4-5 months and then slowly decreased over the next 2-3 years. Also with regard to Middle East Respiratory Syndrome (MERS), the antibody duration in subjects recovered from the disease persisted for at least 34 months. This thesis examines the results of research conducted from the beginning to mid-2021, on 1340 individuals among all the medical staff of the Azienda Ospedaliera Ordine Mauriziano di Torino after both vaccination doses. The purpose is to find, if it exists, a correlation between the persistence of a certain quantity of IgG anti-S antibodies and the body parameters or the type of tasks performed.